Clinical Trial Update: First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI [Phase 2]

View source ↗

Summary

Phase 2 trial assessing first-line regimens for metastatic pancreatic cancer: 5-fluorouracil/leucovorin with nanoliposomal irinotecan (Nal-IRI), gemcitabine wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Gemcitabine (Gemcitabine)
• Leucovorin (folinic acid) (folinic acid)
• Nab-paclitaxel (Abraxane) (nab-paclitaxel)
• Nanoliposomal irinotecan (Nal-IRI) (irinotecan liposome)

Snippet

Sponsor: Federation Francophone de Cancerologie Digestive | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: COMPLETED